Glioblastoma Clinical Trials in Cleveland, Ohio

7 studies are recruiting for glioblastoma in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

   The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurological Institute Brain Tumor Centre Taussig Cancer Cente, Cleveland, Ohio

   Locations

   56 in total

   Run by

   CarThera

   See if you can join NCT05902169 on ClinicalTrials.gov

2. INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

   This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   12 in total

   Run by

   David Reardon, MD

   See if you can join NCT02977780 on ClinicalTrials.gov

3. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   102 in total

   Run by

   NovoCure GmbH

   See if you can join NCT06556563 on ClinicalTrials.gov

4. Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

   The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT05565118 on ClinicalTrials.gov

5. A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

   The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs) that suppress your body's natural immune response against cancer. Sitagli…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT07003542 on ClinicalTrials.gov

6. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

   Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnose…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center*, Cleveland, Ohio

   Locations

   63 in total

   Run by

   Global Coalition for Adaptive Research

   See if you can join NCT03970447 on ClinicalTrials.gov

7. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

   The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Cleveland Clinic, Cleveland, Ohio

   Locations

   8 in total

   Run by

   Orbus Therapeutics, Inc.

   See if you can join NCT05879367 on ClinicalTrials.gov